ResMed (RMD) Scheduled to Post Earnings on Thursday

ResMed (NYSE:RMD) is set to release its earnings data after the market closes on Thursday, April 25th. Analysts expect ResMed to post earnings of $1.93 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, January 24th. The medical equipment provider reported $1.88 EPS for the quarter, beating the consensus estimate of $1.81 by $0.07. ResMed had a net margin of 19.77% and a return on equity of 23.86%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company earned $1.66 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis. On average, analysts expect ResMed to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

ResMed Price Performance

NYSE:RMD opened at $180.35 on Tuesday. ResMed has a one year low of $132.24 and a one year high of $243.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.89 and a current ratio of 3.11. The firm has a market cap of $26.53 billion, a price-to-earnings ratio of 29.81, a PEG ratio of 2.19 and a beta of 0.67. The firm’s fifty day moving average is $186.14 and its two-hundred day moving average is $171.04.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Thursday, February 8th were paid a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 1.06%. The ex-dividend date was Wednesday, February 7th. ResMed’s payout ratio is currently 31.74%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on RMD shares. Royal Bank of Canada increased their target price on shares of ResMed from $181.00 to $182.00 and gave the stock a “sector perform” rating in a research note on Thursday, January 25th. UBS Group increased their target price on shares of ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a research note on Thursday, January 25th. Mizuho reissued a “buy” rating and set a $215.00 target price on shares of ResMed in a research note on Wednesday, March 27th. Oppenheimer raised their price target on shares of ResMed from $185.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. Finally, KeyCorp began coverage on shares of ResMed in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $227.00 price target on the stock. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $199.20.

Insider Buying and Selling at ResMed

In other ResMed news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, General Counsel Michael J. Rider sold 200 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $173.25, for a total transaction of $34,650.00. Following the completion of the sale, the general counsel now owns 6,688 shares in the company, valued at approximately $1,158,696. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Peter C. Farrell sold 10,935 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the sale, the director now owns 157,404 shares of the company’s stock, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,216 shares of company stock worth $2,046,617. Insiders own 1.21% of the company’s stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.